

ESCR 62

THE HOUSE OF REPRESENTATIVES
Thursday, May 27, 2010

ENGROSSED

**Senate Concurrent
Resolution No. 62**

ENGROSSED SENATE CONCURRENT RESOLUTION NO. 62 - By: CRAIN of the Senate and SCHWARTZ of the House.

A Concurrent Resolution encouraging the Medicaid Drug Utilization Review Board within the Oklahoma Health Care Authority to amend certain program; and directing distribution.

- 1 WHEREAS, the Medicaid Drug Utilization Review Board within the Oklahoma
2 Health Care Authority is authorized by Section 5030.5 of Title 63 of the Oklahoma
3 Statutes to recommend and implement product-based prior authorization programs for
4 drugs or drug classes covered under the Oklahoma Medicaid program; and
5 WHEREAS, the Oklahoma Health Care Authority Board approved a product-based
6 prior authorization program for atypical antipsychotics at the Oklahoma Health Care
7 Authority Board meeting on March 11, 2010; and
8 WHEREAS, the product-based prior authorization program for atypical
9 antipsychotics approved by the Oklahoma Health Care Authority Board would classify
10 atypical antipsychotic drugs into three tiers of authorization; and

1 WHEREAS, the product-based prior authorization program for atypical
2 antipsychotics approved by the Oklahoma Health Care Authority Board would require
3 some persons on Medicaid to undergo a fourteen-day trial of one Tier One medication and
4 all Tier Two medications before advancing to a Tier Three medication; and

5 WHEREAS, atypical antipsychotics are used to used to treat psychiatric conditions,
6 including schizophrenia, acute mania, bipolar mania and psychotic agitation; and

7 WHEREAS, delaying the prescription of more effective medications to persons with
8 a serious psychiatric condition could have a negative effect on their health.

9 NOW, THEREFORE, BE IT RESOLVED BY THE SENATE OF THE 2ND
10 SESSION OF THE 52ND OKLAHOMA LEGISLATURE, THE HOUSE OF
11 REPRESENTATIVES CONCURRING THEREIN:

12 THAT the Legislature encourages the Medicaid Drug Utilization Review Board
13 within the Oklahoma Health Care Authority to amend the product-based prior
14 authorization program for atypical antipsychotic medications to require a trial of only
15 one drug per tier before authorizing an atypical antipsychotic in a higher tier.

16 THAT the Secretary of State shall distribute a copy of this resolution to the
17 Oklahoma Health Care Authority Board.

18 DIRECT TO CALENDAR.